Publication | Closed Access

Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies

Fda/cder PerspectivePreclinical Drug EvaluationHealth PolicyBioequivalenceMedicineNonclinical AssessmentsPharmacotherapyNew Approach MethodologiesDrug TrialPharmacologyDrug DiscoveryDrug Analysis